secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jade Biosciences, Inc. (JBIO)
CIK:        0001798749
Form:       8-K
Filed at:   2023-08-14T23:59:59+00:00
Accession:  0001798749-23-000053
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aerovate Q2 net loss $19.0M; cash $150.1M; ATM raised $45M; Phase 2b/3 PAH trial on track
--------------------------------------------------------------------------------

- Net loss of $19.0M for Q2 2023 vs $12.0M in Q2 2022; includes $3.0M stock comp.
- Cash, cash equivalents and available-for-sale securities total $150.1M; runway extended into 2026.
- Sold $45M common stock under ATM program; proceeds fund operations.
- IMPAHCT Phase 2b/Phase 3 trial for AV-101 in PAH has >110 sites active in >20 countries; topline data expected Q2 2024.
- Appointed Habib Dable (ex-Acceleron CEO) to Board of Directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1798749/000179874923000053/0001798749-23-000053-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1798749/000179874923000053/tmb-20230814x8k.htm
  HTML page:      https://secwatch.observer/filing/0001798749-23-000053

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer